New treatment options for delta virus: Is a cure in sight?
Antiviral Agents
/ therapeutic use
Clinical Trials as Topic
Hepatitis D
/ drug therapy
Hepatitis Delta Virus
/ drug effects
Humans
Interferon-alpha
/ therapeutic use
Interleukins
/ therapeutic use
Lipopeptides
/ therapeutic use
Nucleic Acids
/ therapeutic use
Piperidines
/ therapeutic use
Polyethylene Glycols
/ therapeutic use
Polymers
/ therapeutic use
Pyridines
/ therapeutic use
chronic hepatitis delta
interferon lambda
lonafarnib
myrcludex B
treatment
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
23
11
2018
accepted:
25
01
2019
pubmed:
17
2
2019
medline:
23
7
2020
entrez:
17
2
2019
Statut:
ppublish
Résumé
Current treatment of chronic hepatitis D viral infection with interferons is poorly tolerated and effective only in a minority of patients. Despite delta virus causing the most severe form of chronic viral hepatitis, no other treatments are available. After many years of inactivity, there is now hope for new treatment approaches for delta virus and some are likely to enter clinical practice in the near future. Four new treatment approaches are currently being evaluated in phase 2 studies. These involve the hepatocyte entry inhibitor myrcludex B, the farnesyl transferase inhibitor lonafarnib, the nucleic acid inhibitor REP 2139 Ca and pegylated interferon lambda. Results obtained so far are promising, and phase 3 studies are expected shortly. This review summarizes the available data on the efficacy and safety of these new drugs.
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Interleukins
0
Lipopeptides
0
Nucleic Acids
0
Piperidines
0
Polymers
0
Pyridines
0
REP 2139
0
myrcludex-B
0
peginterferon lambda-1a
0T0250N43U
Polyethylene Glycols
3WJQ0SDW1A
lonafarnib
IOW153004F
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
618-626Informations de copyright
© 2019 John Wiley & Sons Ltd.